Spin-offs

AELIX Therapeutics, SL based in Barcelona, is a spin-off of the HIVACAT vaccine research consortium. The company focuses on the discovery and development of immunotherapies against HIV infection. A first round of funding (11.5 million euros) was closed in January 2016. A phase II proof-of-concept clinical trial using the HTI immunogen as a therapeutic vaccine in people with HIV infection is foreseen to be completed by 2020. 

AlbaJuna Therapeutics, SL (2016-2022) is the result of the agreement between IrsiCaixa, Grifols corporation and the researchers Bonaventura Clotet, Jorge Carrillo and Julià Blanco. The spin-off is developing a new treatment strategy based on monoclonal antibodies with great potential to neutralize HIV and activate the “natural killer” cells responsible for destroying cells infected by the virus.